TARS Tarsus Pharmaceuticals
- 34.510
- -0.090-0.26%
- 34.510
- 0.0000.00%
Tarsus Pharmaceuticals News
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price In Tune With Revenues
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Barclays Remains a Buy on Tarsus Pharmaceuticals (TARS)
Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues
Earnings Call Summary | Tarsus Pharmaceuticals(TARS.US) Q2 2024 Earnings Conference
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript
Tarsus Pharmaceuticals Analyst Ratings
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating
Express News | Tarsus Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $60 From $63
Express News | Tarsus Pharmaceuticals Inc : Guggenheim Raises Target Price to $75 From $67
Tarsus Pharmaceuticals GAAP EPS of -$0.88 Beats by $0.08, Revenue of $40.81M Beats by $8.76M
Express News | Tarsus Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results
Tarsus Pharmaceuticals Q2 2024 GAAP EPS $(0.88) Beats $(0.94) Estimate, Sales $40.813M Beat $31.664M Estimate
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Reports Q2 Loss $-0.88, Vs. Street Est of $-0.80
Tarsus Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Express News | Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Express News | Tarsus Pharmaceuticals Q2 Operating Expenses USD 74.115 Million
Express News | Tarsus Pharmaceuticals Q2 Net Income USD -33.29 Million Vs. IBES Estimate USD -33.2 Million
Express News | Tarsus Pharmaceuticals Q2 Basic EPS USD -0.88
Analysis
Price Target
No Data
No Data